Allergen reduction agent and allergen reduction coating

Abstract

The present invention provides an allergen reduction agent that demonstrates an excellent allergen reduction effect, and a coating including the allergen reduction agent. The allergen reduction agent according to the present invention includes, as an active ingredient, an imide compound having a specified imide structure or a salt of said structure in a molecule thereof, and thereby demonstrates an excellent allergen reduction effect via the action of the imide compound. Moreover, the allergen reduction agent is incorporated in a base material such as a coating material to form an allergen reduction product, and the base material containing the allergen reduction agent exhibits an allergen reduction effect.

Description

Allergen reducing agents and allergen reducing paints

[0001] This invention relates to an allergen reducing agent and an allergen reducing paint.

[0002] In recent years, many allergic diseases such as atopic dermatitis, bronchial asthma, and allergic rhinitis have become a problem. The main cause of these allergic diseases is the increase in allergens in living spaces, such as dust mites that inhabit homes, particularly house dust mites (Der1, Der2), which are abundant in indoor dust, and cedar pollen allergens (Cry j1, Cry j2), which are mainly suspended in the air in large quantities during the spring.

[0003] The allergens from house dust mites are not the mites themselves, but rather their carcasses and feces. Therefore, eliminating house dust mites does not provide a fundamental solution to allergic diseases.

[0004] Furthermore, Cry j1 and Cry j2, which are cedar pollen allergens, are glycoproteins with molecular weights of approximately 40 kDa and approximately 37 kDa, respectively, and have complex three-dimensional structures folded in a spiral or sheet-like manner. When these cedar pollen allergens adhere to the nasal mucosa, they are recognized as foreign substances outside the body and trigger an inflammatory response.

[0005] Therefore, there is a need for technologies that can remove allergens from living spaces or inactivate them by denaturing them.

[0006] Patent Document 1 discloses an interior decorative sheet having anti-allergen properties, wherein the interior decorative sheet comprises at least a base sheet with a pattern layer and a surface protective layer made of a curable resin, and the surface protective layer is blended with an anionic phenolic material having anti-allergen properties and a zinc-based material having anti-allergen properties.

[0007] Japanese Patent Publication No. 2014-69320

[0008] However, the allergen treatment ability (allergen reduction effect) of the anti-allergen anionic phenol-based material and anti-allergen zinc-based material used in the interior decorative sheet having anti-allergen properties disclosed in Patent Document 1 is insufficient, and there is a need for an allergen reducing agent that exhibits an excellent allergen reduction effect.

[0009] This invention provides an allergen reducing agent that exhibits excellent allergen reduction effects, and an allergen reducing paint containing this allergen reducing agent.

[0010] The allergen reducing agent of the present invention is characterized by containing an imide compound having the structure shown in formula (1) or formula (2) below as an active ingredient. However, in formula (1), X is a countercation that forms a salt. In formulas (1) and (2), * is a bond and means a single bond.

[0011] The allergen-reducing paint of the present invention is characterized by comprising a paint and the allergen-reducing agent contained in the paint.

[0012] The allergen reducing agent of the present invention exhibits excellent allergen reducing effects through the action of imide compounds.

[0013] In the numerical ranges described stepwise in this specification, the upper or lower limit of one step in the numerical range can be arbitrarily combined with the upper or lower limit of another step in the numerical range. In the numerical ranges described in this specification, the upper or lower limit of that numerical range may be replaced with values ​​shown in the examples or values ​​that can be uniquely derived from the examples. In this specification, numbers connected by "~" mean a numerical range that includes the numbers before and after "~" as the lower and upper limits.

[0014] (Imide Compounds) The allergen reducing agent contains an imide compound having the structure shown in formula (1) or formula (2) below as an active ingredient. However, in formula (1), X is a countercation that forms a salt. In the present invention, * represents a bond and means a single bond.

[0015] In formula (2), X is a countercation that forms a salt, and a monovalent countercation is preferred. Examples of X include alkali metal ions such as sodium ions and potassium ions, and ammonium ions. Alkali metal ions are preferred, and sodium ions and potassium ions are more preferred, as they exhibit excellent allergen-reducing effects in the allergen-reducing agent.

[0016] Allergens cause allergic diseases due to some of the proteins they contain. The protein portion that causes allergic diseases (the causative protein portion) is only a few nanometers to tens of nanometers in size, which is small even when compared to viruses and bacteria. Furthermore, the causative protein portion has a complex three-dimensional structure, folded in a helical or sheet-like manner.

[0017] The structural parts of the imide compound shown in formulas (1) and (2) exert their allergen-reducing effect by effectively interacting with the allergen-causing protein portion. As mentioned above, the allergen-causing protein portion is small compared to viruses and bacteria, and it cannot be said that a structural part that exhibits antiviral properties necessarily exhibits the allergen-reducing effect described later. Furthermore, antibacterial agents work by suppressing the growth of bacteria, which is different from the action of reducing allergic diseases by acting on the causative protein portion, and it cannot be said that a compound that exhibits antibacterial properties necessarily exhibits the allergen-reducing effect described later.

[0018] The inventors, taking into consideration the unique characteristics of allergens, such as the difference between the overall size of the allergen and the size of the causative protein portion that causes allergic diseases, as a result of various studies, have found that the allergen reducing agent of the present invention exhibits an excellent allergen reducing effect because the structural portion represented by formula (1) or formula (2) in the above-mentioned imide compound effectively interacts with the causative protein portion of the allergen.

[0019] Thus, the allergen-reducing particles of the present invention were developed in view of the allergen-specific circumstances, in which, unlike viruses, the overall size of the allergen and the size of the causative protein portion that causes allergic diseases differ.

[0020] The imide compound is not particularly limited as long as it has the structure shown in formula (1) or formula (2) above. Since the imide compound is excellent in the allergen-reducing effect of the allergen reducing agent, it is preferable that the structure shown in formula (1) or formula (2) constitutes part of a ring structure, and it is preferable that the structure shown in formula (1) or formula (2) constitutes part of a five-membered ring structure or a six-membered ring structure, and it is preferable that it has the structure shown in formula (1a) or formula (2a). In formulas (1a) and (2a), the double line of solid and dotted lines represents a single bond, a double bond, or a resonance structure of a single bond and a double bond.

[0021]

[0022] The imide compound may have a fused ring formed by a ring structure in which the structure shown in formula (1) or formula (2) partially constitutes, and another ring structure. The other ring structure is not particularly limited and includes, for example, aromatic ring structures such as benzene rings, naphthalene rings, and anthracene rings, and alicyclic ring structures such as cyclohexane rings and cyclopentane rings.

[0023] Examples of imide compounds include phthalimide, cyclohexane-1,2-dicarboxymide, succinimide, 4-aminophthalimide, 4-bromophthalimide, glutarimide, maleimide, and salts of these compounds (e.g., alkali metal salts such as sodium salts and potassium salts, ammonium salts, etc.). Phthalimide and alkali metal salts of phthalimide are preferred, and sodium salts of phthalimide and potassium salts of phthalimide are more preferred. The imide compounds may be used individually or in combination of two or more.

[0024] The imide compound is preferably a polymer having repeating units containing the structure shown in formula (1) or formula (2) above. Having repeating units containing the structure shown in formula (1) or formula (2) results in the structure shown in formula (1) or formula (2) being repeatedly present in the main chain, facilitating contact with the causative protein portion which has a complex three-dimensional structure folded in a helical or sheet-like manner, enabling effective interaction with the allergen and resulting in an excellent allergen reduction effect.

[0025] In a polymer having repeating units containing the structure shown in formula (1) or formula (2), the repeating units containing the structure shown in formula (1) or formula (2) are preferably the structure shown in formula (3) or formula (4), and preferably the structure shown in formula (3a) or formula (4a). In formulas (3) and (3a), n1 is the number of repeating units, which is an integer of 2 or more, preferably an integer of 10 or more, and more preferably an integer of 30 or more. In formula (3), A 1 is an alkylene group. In formulas (4) and (4a), n2 is the number of repeating units, which is an integer of 2 or more, preferably an integer of 10 or more, and more preferably an integer of 30 or more. In formula (4), A 2 This is an alkylene group.

[0026]

[0027]

[0028] In the present invention, an alkylene group is a divalent atomic group formed by removing (extracting) one hydrogen atom from each of the different carbon atoms bonded to aliphatic saturated hydrocarbons, or a divalent atomic group formed by removing (extracting) two hydrogen atoms from methane, and includes both linear and branched atomic groups.

[0029] A 1 and A 2Examples of the alkylene group represented by include a methylene group [—CH2—], an ethylene group [—CH2—CH2—], a propylene group [—CH(CH3)—CH2—], a trimethylene group [—CH2—CH2—CH2—], a butylene group, —CH2—C(CH3)2—, an amylene group [—(CH2)5—], a hexylene group, and the like. Note that A 1 and A 2 may be the same or different.

[0030] A 1 and A 2 In and , the number of carbon atoms of the alkylene group is preferably 2 or more, more preferably 3 or more. A 1 and A 2 In and , the number of carbon atoms of the alkylene group is preferably 8 or less, more preferably 7 or less, still more preferably 6 or less, and even more preferably 5 or less. When the number of carbon atoms of the alkylene group is within the above range, the interaction between the structural part represented by Formula (1) or Formula (2) and the allergenic causative protein is excellent, and the allergen reducing agent exhibits an excellent allergen reducing effect.

[0031] When the imide compound is a polymer having a repeating unit containing the structure represented by the above Formula (1) or Formula (2), it preferably further has a repeating unit containing the structure represented by Formula (5) or Formula (6), and more preferably further has a repeating unit containing the structure represented by Formula (5a) or Formula (6a). Although the mechanism is not clear, the carboxy group generated by hydrolysis of the acid anhydride moiety contained in Formula (5) or Formula (5a), or the salt structure of the carboxy group contained in Formula (6) or Formula (6a), is present in the vicinity of the structure represented by Formula (1) or Formula (2), so that it is more easily folded into a helical or sheet-like shape to have a complex three-dimensional structure and contact with the causative protein part, and the interaction with the allergen can be carried out more effectively, and a more excellent allergen reducing effect can be achieved. In Formula (5) and Formula (5a), m1 is the number of repeating units, which is an integer of 2 or more, preferably an integer of 10 or more, and more preferably an integer of 30 or more. In Formula (5), A 3is an alkylene group. In Formula (6) and Formula (6a), m2 is the number of repeating units, which is an integer of 2 or more, preferably an integer of 10 or more, and more preferably an integer of 30 or more. In Formula (6), A 4 is an alkylene group. Z is a counter cation that forms a salt.

[0032] In Formula (5),

[0033]

[0034]

[0035] A 3 and A 4 Examples of the alkylene group represented by include a methylene group [—CH2—], an ethylene group [—CH2—CH2—], a propylene group [—CH(CH3)—CH2—], a trimethylene group [—CH2—CH2—CH2—], a butylene group, —CH2—C(CH3)2—, an amylene group [—(CH2)5—], a hexylene group, and the like. Note that A 3 and A 4 may be the same or different.

[0036] A 3 and A 4 In, the number of carbon atoms of the alkylene group is preferably 2 or more, and more preferably 3 or more. In A 1 and A 2 In, the number of carbon atoms of the alkylene group is preferably 8 or less, more preferably 7 or less, still more preferably 6 or less, and even more preferably 5 or less. When the number of carbon atoms of the alkylene group is within the above range, the interaction between the structural part shown in Formula (1) or Formula (2) and the allergenic causative protein can be improved, and the allergen reducing agent exhibits an excellent allergen reducing effect.

[0037] In Formula (6), Z is a counter cation that forms a salt, and a monovalent counter cation is preferable. Examples of Z include alkali metal ions such as hydrogen ion, sodium ion, potassium ion, ammonium ion, and the like. Since the allergen reducing agent has an excellent allergen reducing effect, hydrogen ion and alkali metal ions are preferable, and sodium ion and potassium ion are more preferable.

[0038] When the imide compound is a polymer, polymers having the repeating units shown in formula (3) and formula (5) [formula (7)], polymers having the repeating units shown in formula (3) and formula (6) [formula (8)], polymers having the repeating units shown in formula (4) and formula (5) [formula (9)], and polymers having the repeating units shown in formula (4) and formula (6) [formula (10)] are preferred, and polymers having the structure shown in formula (7), polymers having the structure shown in formula (8), and polymers having the structure shown in formula (10) are more preferred. When the imide compound has the above repeating units, the allergen reducing agent exhibits an excellent allergen reducing effect. These polymers may be used individually or in combination of two or more. The polymers having the structures shown in formulas (7) to (10) may be used individually or in combination of two or more.

[0039]

[0040] When the imide compound is a polymer, the weight-average molecular weight of the imide compound is preferably 10,000 or more, more preferably 20,000 or more, more preferably 30,000 or more, and more preferably 40,000 or more. The weight-average molecular weight of the imide compound is preferably 500,000 or less, more preferably 400,000 or less, more preferably 300,000 or less, more preferably 200,000 or less, more preferably 100,000 or less, more preferably 80,000 or less, and more preferably 70,000 or less. The weight-average molecular weight of the imide compound is preferably 10,000 to 500,000, and more preferably 40,000 to 80,000. If the weight-average molecular weight of the imide compound is 10,000 or more, the interaction between the structural part shown in formula (1) or formula (2) and the anhydride part of the carboxyl group (-CO-O-CO-) or the carboxyl group or its salt can be improved, thereby enhancing the interaction between the imide compound and the allergen-causing protein part, resulting in superior allergen-reducing effect of the allergen-reducing agent. If the weight-average molecular weight of the imide compound is 500,000 or less, the entanglement of the polymer chain of the imide compound is reduced, which can improve the interaction between the imide compound and the allergen-causing protein part.

[0041] In this invention, the weight-average molecular weight of the polymer is the polystyrene-converted value measured by GPC (gel permeation chromatography). When multiple peak tops are detected by GPC, the area value of each peak is considered as a weight to calculate the weight-average molecular weight, and this value is taken as the weight-average molecular weight of the polymer.

[0042] For example, measurements can be taken using the following measuring device and conditions: Gel permeation chromatograph: Waters Corporation product name "Alliance HPLC" Column: Resonaq Corporation product name "OHpak SB-805" Detector: Differential refractometer Sample flow rate: 1 mL / min Column temperature: 40°C Elutate: 0.2 M Na2CO3 aq. 60 vol% / acetonitrile 40 vol%

[0043] When the imide compound is a polymer, it is preferable that the imide compound contains a crosslinked structure. The presence of a crosslinked structure in the imide compound improves the water resistance of the allergen-reducing effect of the allergen-reducing agent.

[0044] One method for introducing a crosslinked structure into an imide compound is to crosslink the imide compound using a crosslinking agent. The crosslinking agent is not particularly limited as long as it can crosslink the imide compound, and examples include isocyanate-based crosslinking agents, epoxy-based crosslinking agents, oxazoline-based crosslinking agents, aziridine-based crosslinking agents, and carbodiimide-based crosslinking agents.

[0045] The epoxy crosslinking agent is not particularly limited, and examples include glycidylaniline, 1,3-bis(N,N-diglycidylaminomethyl)cyclohexane, 1,6-hexanediol diglycidyl ether, neopentyl glycol diglycidyl ether, ethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, polyethylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether, sorbitol polyglycidyl ether, glycerol polyglycidyl ether, pentaerythritol polyglycidyl ether, polyglycerol polyglycidyl ether, sorbitan polyglycidyl ether, trimethylolpropane polyglycidyl ether, diglycidyl adipic acid ester, diglycidyl o-phthalate ester, triglycidyl-tris(2-hydroxyethyl) isocyanurate, resorcinol diglycidyl ether, and bisphenol-S-diglycidyl ether.

[0046] The isocyanate crosslinking agent is not particularly limited and includes, for example, lower aliphatic polyisocyanates such as butylene diisocyanate and hexamethylene diisocyanate; alicyclic isocyanates such as cyclopentylene diisocyanate, cyclohexylene diisocyanate, and isophorone diisocyanate; aromatic isocyanates such as 2,4-tolylene diisocyanate, 4,4'-diphenylmethane diisocyanate, and xylylene diisocyanate; and trimethylolpropane. Examples of isocyanate adducts include n / tolylene diisocyanate trimer adducts (e.g., Mitsui Chemicals' "Takenate D101E"), trimethylolpropane / hexamethylene diisocyanate trimer adducts (e.g., Tosoh's "Coronate HL"), xylylene diisocyanate trimethylolpropane adducts (e.g., Mitsui Chemicals' "Takenate D110N"), and hexamethylene diisocyanate isocyanurates (e.g., Tosoh's "Coronate HX").

[0047] The solubility of the imide compound in water at 25°C is preferably 30 g / 100 g or less, more preferably 20 g / 100 g or less, and even more preferably 10 g / 100 g or less. The solubility of the imide compound in water at 25°C is preferably 0.01 g / 100 g or more, more preferably 0.1 g / 100 g or more, and even more preferably 0.15 g / 100 g or more. The solubility of the imide compound in water at 25°C is preferably 0.01 to 30 g / 100 g. When the solubility of the imide compound in water at 25°C is 0.01 g / 100 g or more, the interaction between the imide compound and the allergen-causing protein portion can be improved. When the solubility of the imide compound in water at 25°C is 30 g / 100 g or less, the water resistance of the allergen-reducing effect of the allergen-reducing agent is improved.

[0048] In this invention, the solubility of an imide compound in water at 25°C (g / 100g) refers to the mass (g) of the imide compound that can be dissolved in 100g of water, and also refers to the mass (g) of the imide compound dissolved in 100g of water in a saturated aqueous solution at 25°C. Specifically, the solubility of an imide compound in water at 25°C refers to the value measured at 25°C in accordance with OECD Chemical Testing Guidelines No. 105 (Water Solubility).

[0049] The pH of a 1.0% by mass aqueous solution of an imide compound at 25°C is preferably 10.0 or less, more preferably 9.0 or less, and more preferably 8.8 or less. The pH of a 1.0% by mass aqueous solution of an imide compound at 25°C is preferably 2.0 or higher, more preferably 3.0 or higher, more preferably 3.5 or higher, more preferably 4.0 or higher, more preferably 4.5 or higher, more preferably 5.5 or higher, more preferably 6.5 or higher, more preferably 7.0 or higher, more preferably 7.5 or higher, and more preferably 8.0 or higher. The pH of a 1.0% by mass aqueous solution of an imide compound at 25°C is preferably 2.0 to 10.0, and more preferably 3.0 to 9.0. When the pH of a 1.0% by mass aqueous solution of an imide compound at 25°C is within the above range, the surface of the imide compound enters an appropriate charge state, the electrostatic interaction between the imide compound and the allergen-causing protein increases, and the allergen-reducing effect of the allergen-reducing agent improves.

[0050] The pH of a 1.0% by mass aqueous solution of an imide compound at 25°C refers to the pH value at 25°C of a solution obtained by adding 1.0 g of the imide compound to 99.0 g of purified water and mixing them uniformly. If the imide compound is a mixture, the pH of the imide compound refers to the pH of the entire mixture.

[0051] [Allergen Reducing Agents] Allergen reducing agents have an allergen-reducing effect against various allergens through the action of imide compounds.

[0052] Allergens targeted by allergen reducing agents include animal allergens such as dust mite allergens (Der1, Der2), allergens caused by dogs and cats (Can f1, Fel d1), and plant allergens such as cedar pollen allergens (Cryj1, Cryj2) and pollen that float in the air. While any type of mite allergen can be targeted, particularly those found in indoor dust, especially bedding, and are a common cause of allergic diseases, this product is especially effective against house dust mites, particularly house dust mites, which are abundant in indoor dust and bedding. It is particularly effective against house dust mites, which are a common cause of allergic diseases. (These include mites with dorsal spiracles, mites with tetraspiracles, mites with posterior spiracles, mites with posterior spiracles, mites with mesospiracles, mites with mesospiracles, mites with anterior spiracles, mites with stag beetle mites and broad mites, house dust mites such as Dermatophagoides pteronyssinus, house dust mites with anaspiracles, and house dust mites with hidden spiracles.)

[0053] Here, an allergen reducing agent refers to a substance that has an allergen reducing effect. The allergen reducing effect can be determined by measuring the allergen reduction rate of cedar pollen allergen (Cryj1) or dust mite allergen (Derf1) in the following manner, and if the allergen reduction rate for at least one of the allergens is 60% or higher, it can be determined that the substance has an allergen reducing effect.

[0054] The allergen-reducing effect of an allergen-reducing agent can be measured, for example, in the following manner: To 10 parts by mass of an allergen-reducing agent, a binder resin (Resonac Co., Ltd. product name "Polysol AM-200", solvent: water, solids content: 40% by mass) is added to produce 90 parts by mass of solids to create an allergen-reducing coating.

[0055] Next, a polyester film is prepared as the base material. An allergen-reducing coating is applied to one side of this base material so that the film thickness after drying is 10 μm. Then, it is dried in an oven at 120°C for 1 hour to produce an allergen-reducing product in which a coating film is formed on one side.

[0056] The freeze-dried powder of the above allergen is dissolved in purified water to prepare an allergen aqueous solution containing 10 μg / mL of the allergen. Then, 0.05 w / v% polysorbate 20-containing phosphate-buffered saline (pH: 7.4, hereinafter referred to as "PBS-T") is added to the allergen aqueous solution and mixed uniformly to prepare an allergen solution containing 15 ng / mL of the allergen.

[0057] The above allergen-reducing product is cut into a flat square shape with sides of 5 cm, 0.4 mL of the above allergen solution is dropped onto the coating film, and then the product is covered with a flat square polyethylene film with sides of 4 cm and left at 25°C for 24 hours to prepare the test solution.

[0058] Next, the amount of allergen W1 (ng / mL) present in the test solution is measured using the measurement reagent.

[0059] Except for using a binder resin (Resonac Co., Ltd. product name "Polysol AM-200", solvent: water, solids content: 40% by mass) as a blank coating instead of the allergen-reducing coating, the amount of allergen W0 (ng / mL) present in the test solution is measured in the same manner as above. The allergen reduction rate (%) is calculated based on the following formula: Allergen reduction rate (%) = 100 - (W1 / W0) × 100

[0060] For example, as the cedar pollen allergen (Cryj1), you can use the product commercially available from ITEA under the product name "Cedar Pollen Extract, Code 4-CJ-001". As the dust mite allergen (Derf1), you can use the product commercially available from ITEA under the product name "Dust Mite Allergen Extract, Code 4-DF-001".

[0061] The allergen reduction rate of the allergen reducing agent is preferably 70% or more, more preferably 80% or more, more preferably 85% or more, more preferably 90% or more, and more preferably 95% or more.

[0062] The method for producing an allergen reducing agent is not particularly limited. For example, an allergen reducing agent can be produced by mixing an imide compound, which is the active ingredient, with a general-purpose additive as needed, in a general manner.

[0063] This document explains the usage of allergen reducing agents. Allergen reducing agents exert an allergen-reducing effect against various allergens through the action of imide compounds. Allergen reducing agents can reduce allergens by inactivating them upon contact.

[0064] Allergen reducing agents are used, for example, by being incorporated into a substrate to which an allergen reducing effect is desired, thereby constituting an allergen-reducing product. A substrate containing an allergen reducing agent exhibits an allergen-reducing effect as an allergen-reducing product. The form in which the allergen reducing agent is incorporated into the substrate is not particularly limited, and examples include mixing the allergen reducing agent into the substrate, attaching the allergen reducing agent to the surface of the substrate, or kneading the allergen reducing agent into the substrate.

[0065] An allergen reducing agent can be dissolved or dispersed in a solvent to form an allergen reducing solution, and by coating this allergen reducing solution onto a substrate, the allergen reducing agent can be attached to the substrate surface. The allergen reducing solution may also contain additives such as oils, emulsions, and suspensions, as needed.

[0066] Examples of the solvents mentioned above include water (preferably deionized water), alcohols (methyl alcohol, ethyl alcohol, propyl alcohol, etc.), hydrocarbons (toluene, xylene, methylnaphthalene, kerosene, cyclohexane, etc.), ethers (diethyl ether, tetrahydrofuran, dioxane, etc.), ketones (acetone, methyl ethyl ketone, etc.), and amides (N,N-dimethylformamide, etc.), with water being preferred.

[0067] The content of the allergen reducing agent in 100% by mass of the allergen reducing solution is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and more preferably 1% by mass or more. The content of the allergen reducing agent in 100% by mass of the allergen reducing solution is preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 10% by mass or less. The content of the allergen reducing agent in 100% by mass of the allergen reducing solution is preferably 0.01 to 20% by mass, and more preferably 0.1 to 15% by mass.

[0068] The substrates for which the allergen reducing agent is contained are not particularly limited as long as they can contain the allergen reducing agent, and examples include synthetic resin molded articles, paints, wallpaper, decorative sheets, flooring materials, fibers, textile products (woven fabrics, nonwoven fabrics, knitted fabrics, cloths), interior accessories and interior materials for vehicles (e.g., cars, airplanes, ships, etc.) (seats, child seats and the foams that make them up, etc.), kitchenware, baby products, and building interior materials.

[0069] The synthetic resin constituting the molded synthetic resin article is not particularly limited and includes, for example, thermoplastic resins (e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, Teflon®, acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyethersulfone, polyarylate, polyetheretherketone, thermoplastic polyimide, polyamideimide, etc.) and thermosetting resins (e.g., phenolic resin, epoxy resin, melamine resin, urea resin, unsaturated polyester resin, alkyd resin, silicone resin, polyurethane, thermosetting polyimide, etc.). The synthetic resin may be used alone or in combination of two or more types.

[0070] The allergen reducing agent may be kneaded into the synthetic resin. One method of kneading the allergen reducing agent into the synthetic resin is to mix the allergen reducing agent with the raw material synthetic resin to create a resin composition. Using this resin composition, an allergen-reducing product of the desired shape can be obtained as a molded article by a general-purpose synthetic resin molding method. Examples of general-purpose synthetic resin molding methods include extrusion molding, injection molding, and blow molding. Alternatively, the synthetic resin and the allergen reducing agent may be mixed to form a masterbatch for synthetic resin molding, which can then be mixed with the raw material synthetic resin to produce a molded allergen-reducing product using a general-purpose synthetic resin molding method.

[0071] The content of the allergen reducing agent in 100% by mass of the resin composition is preferably 1% by mass or more, more preferably 3% by mass or more, and more preferably 5% by mass or more. The content of the allergen reducing agent in 100% by mass of the resin composition is preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 10% by mass or less. The content of the allergen reducing agent in 100% by mass of the resin composition is preferably 1 to 20% by mass, more preferably 3 to 15% by mass, and more preferably 3 to 10% by mass.

[0072] The content of the allergen reducing agent in 100% by mass of the masterbatch for molding synthetic resin is preferably 20% by mass or more, more preferably 30% by mass or more, and more preferably 50% by mass or more. The content of the allergen reducing agent in 100% by mass of the masterbatch for molding synthetic resin is preferably 80% by mass or less, more preferably 70% by mass or less, and more preferably 60% by mass or less. The content of the allergen reducing agent in 100% by mass of the masterbatch for molding synthetic resin is preferably 20 to 80% by mass, and more preferably 30 to 70% by mass.

[0073] This section describes a method for producing allergen-reducing fibers by physically fixing an allergen-reducing agent to fibers. Examples of methods for physically fixing an allergen-reducing agent to fibers include: (1) dispersing the allergen-reducing agent in a solvent (preferably water) to prepare an allergen-reducing solution, impregnating the fibers in this solution, and fixing the allergen-reducing agent to the fibers; (2) applying or spraying the above allergen-reducing solution onto the fiber surface; (3) immersing the fibers in a binder resin containing the above allergen-reducing agent, and fixing the allergen-reducing agent to the fibers with the binder resin; and (4) applying or spraying the above allergen-reducing agent in a binder resin onto the fiber surface, and fixing the allergen-reducing agent to the fibers with the binder resin. Allergen-reducing fiber products can be produced by using textile products as the fibers. Furthermore, in the methods described in (1) and (2) above, a binder resin may be included in the allergen reduction solution. The solvent is the same as described above, so its explanation is omitted.

[0074] The binder resin is not particularly limited as long as it can fix the allergen reducing agent to the fiber surface. For example, examples of binder resins include urethane resins such as one-component urethane resins and two-component urethane resins, silicone resins, acrylic resins, urethane acrylate resins, polyester resins, unsaturated polyester resins, alkyd resins, vinyl acetate resins, vinyl chloride resins, epoxy resins, and epoxy acrylate resins, with urethane resins being preferred.

[0075] Allergen-reducing paints can be manufactured by incorporating allergen-reducing agents into the paint. The paint film produced from these allergen-reducing paints exhibits excellent allergen-reducing effects.

[0076] Conventional known paints are used as coatings, including, for example, oil-based paints (e.g., mixed paints, oil varnishes, etc.), cellulose coatings, synthetic resin coatings, and water-based coatings. The coatings also include photocurable coatings that polymerize upon irradiation with radiation such as ultraviolet light to produce binder resin components. Water-based coatings contain the water-based solvent and binder resin described later.

[0077] The paint contains a binder resin, but this binder resin is not particularly limited as long as it can fix the allergen reducing agent to the substrate surface. Examples of binder resins include urethane resins such as one-component urethane resins and two-component urethane resins, silicone resins, acrylic resins, urethane acrylate resins, polyester resins, unsaturated polyester resins, alkyd resins, vinyl acetate resins, vinyl chloride resins, epoxy resins, and epoxy acrylate resins, with vinyl chloride resins being preferred.

[0078] Paints may contain additives such as pigments, plasticizers, hardeners, fillers, antioxidants, thickeners, and surfactants, to the extent that they do not impair the physical properties of the paint. Methods for producing allergen-reducing paints by incorporating allergen-reducing agents into the paint include, for example, supplying the allergen-reducing agent and the paint to a dispersion device and mixing them uniformly. Examples of dispersion devices include high-speed mills, ball mills, and sand mills.

[0079] The paint may contain a solvent to adjust its viscosity. The solvent may be either an aqueous solvent or an organic solvent, but an organic solvent is preferred because it improves the dispersibility of the allergen reducing agent in the paint. The organic solvent is not particularly limited and includes, for example, toluene, xylene, methyl ethyl ketone, acetone, ethyl acetate, and benzene. The aqueous solvent is not particularly limited and includes, for example, water and lower alcohols (alcohols with 4 or fewer carbon atoms, such as methanol, ethanol, propanol, and butanol), with a preferred aqueous medium containing 50% by mass or more of water. The organic solvent and aqueous solvent may be used individually or in combination of two or more.

[0080] The content of the allergen reducing agent in 100% by mass of the allergen-reducing paint is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and more preferably 1% by mass or more. The content of the allergen reducing agent in 100% by mass of the allergen-reducing paint is preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 10% by mass or less. The content of the allergen reducing agent in 100% by mass of the allergen-reducing paint is preferably 0.01 to 20% by mass.

[0081] Building interior materials are not particularly limited and can include, for example, flooring, wallpaper, ceiling materials, paint, doorknobs, switches, switch covers, and wax.

[0082] Vehicle interior accessories and vehicle interior materials are not particularly limited and may include, for example, seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trims, instrument panels, consoles, glove boxes, straps, handrails, etc.

[0083] The present invention will be described more specifically below with reference to examples, but the present invention is not limited thereto. Specific numerical values ​​such as blending ratios (content), physical properties, and parameters used in the following description may be replaced with the corresponding upper limits (numerical values ​​defined as "less than or equal to" or "less than") or lower limits (numerical values ​​defined as "greater than or equal to") of the blending ratios (content), physical properties, and parameters described in the "Means for Solving the Problem" and "Modes for Carrying Out the Invention" sections.

[0084] The following imide compounds and other compounds were prepared. [Imide compounds] ・Phthalimide [Formula (A)] ・Phthalimide potassium [Formula (B)] ・Imide compound 1 [An imide compound having the structure shown in Formula (C), where n1 and m1 are integers of 2 or more, weight-average molecular weight: 60000, trade name "Isoban 304" manufactured by Kuraray Co., Ltd.] ・Imide compound 2 [An imide compound having the structure shown in Formula (D), where n1 and m2 are integers of 2 or more, in Formula (D), part of (-CONHCO-) ​​is (-CON - Na + It is in the form of a salt (CO-), weight-average molecular weight: 60,000, a polymer sold commercially by Kuraray under the trade name "Isoban 304", NaOH neutralized solution, solid content: 25% by mass.

[0085]

[0086]

[0087]

[0088] [Other compounds] ・N-butylphthalimide [Formula (E)] ・Potential polymer 1 [Formula (F), where p is the number of repeating units]

[0089]

[0090] [Crosslinking agent] ・Epoxy crosslinking agent (sorbitol polyglycidyl ether, Nagase ChemteX Co., Ltd. product name "Denacol EX-614B")

[0091] (Examples 1-4, Comparative Examples 1 and 2) Allergen reducing agents were prepared using the imide compounds shown in Table 1 as active ingredients. In Example 4, the content of imide compound 2 shown in Table 1 refers to the solid content, i.e., the amount of imide compound 2 itself.

[0092] (Example 5) An allergen reducing agent was prepared by mixing 90 parts by mass of the solid content of imide compound 2 [Formula (D)] with 10 parts by mass of an epoxy crosslinking agent to introduce a crosslinked structure into imide compound 2. The content of imide compound 2 shown in Table 1 represents the amount of solid content, i.e., the amount of imide compound 2 itself.

[0093] The solubility of imide compounds in water at 25°C and the pH of a 1.0% by mass aqueous solution of the imide compound at 25°C were measured using the procedure described above, and the results are shown in Table 1. In Table 1, "solubility in water at 25°C" and "pH of a 1.0% by mass aqueous solution of the imide compound at 25°C" are denoted as "water solubility" and "pH," respectively.

[0094] The allergen reduction rate (allergen reduction effect) of the obtained allergen reducing agent was measured according to the following procedure, and the results are shown in Table 1. In Table 1, "≧F" (where F is a number) means "greater than or equal to F", and "<F" means "less than F".

[0095] [Allergen reduction effect (coating film)] Freeze-dried powder of dust mite allergen (Derf1) (ITEA Co., Ltd. product name "Dust mite allergen extract, code 4-DF-001") and freeze-dried powder of pollen allergen (Cryj1) (ITEA Co., Ltd. product name "Japanese cedar pollen extract, code 4-CJ-001") were prepared.

[0096] For the allergen reducing agents of Examples 1 to 4 and Comparative Examples 1 and 2, an allergen reducing coating was prepared by adding a binder resin (Resonac Co., Ltd. product name "Polysol AM-200", solvent: water, solids content: 40% by mass) to 10 parts by mass of the allergen reducing agent, so that the solids content amounted to 90 parts by mass.

[0097] For the allergen reducing agent of Example 5, an allergen reducing coating was prepared by adding a binder resin (Resonac Co., Ltd. product name "Polysol AM-200", solvent: water, solids content: 40% by mass) to 10 parts by mass of the solids content of the allergen reducing agent, so that the total solids content was 90 parts by mass.

[0098] Next, a polyester film was prepared as the base material. An allergen-reducing coating was applied to one side of this base material so that the film thickness after drying would be 10 μm. Then, it was dried in an oven at 120°C for 1 hour to produce an allergen-reducing product in which a coating film was formed on one side.

[0099] The freeze-dried powder of the above allergen was dissolved in purified water to prepare an allergen aqueous solution containing 10 μg / mL of the allergen. Then, PBS-T (phosphate buffer containing 0.05% by mass of Tween 20 (manufactured by Tokyo Chemical Industry Co., Ltd.), pH: 7.4) was added to the allergen aqueous solution and mixed uniformly to prepare an allergen solution containing 15 ng / mL of the allergen.

[0100] The above allergen-reducing product was cut into a flat square shape with sides of 5 cm, 0.4 mL of the above allergen solution was dropped onto the coating film, and then the product was covered with a flat square polyethylene film with sides of 4 cm and left at 25°C for 24 hours to prepare the test solution.

[0101] Next, the amount of allergen W1 (ng / mL) in the test solution was measured using the above-mentioned measurement reagent.

[0102] Except for using a binder resin (Resonac Co., Ltd. product name "Polysol AM-200", solvent: water, solids content: 40% by mass) as a blank coating instead of the allergen-reducing coating, the amount of allergen W0 (ng / mL) present in the test solution was measured in the same manner as described above. The allergen reduction rate (%) was calculated based on the following formula: Allergen reduction rate (%) = 100 - (W1 / W0) × 100

[0103]

[0104] (Cross-reference of related applications) This application claims priority under Japanese Patent Application No. 2024-192274, filed on 31 October 2024, and the disclosures of this application are incorporated herein by reference to those applications in their entirety.

[0105] The present invention allows for the production of allergen-reducing products with excellent allergen-reducing effects by incorporating the present invention into a substrate to which an allergen-reducing effect is desired.

Claims

1. An allergen reducing agent characterized by containing an imide compound having the structure shown in formula (1) or formula (2) below as an active ingredient. However, in formula (1), X is a countercation that forms a salt. In formulas (1) and (2), * is a bond and means a single bond.

2. The allergen reducing agent according to claim 1, characterized in that the imide compound comprises at least one imide compound selected from the group consisting of phthalimide, cyclohexane-1,2-dicarboxymide, succinimide, 4-aminophthalimide, 4-bromophthalimide, glutarimide, maleimide, and salts thereof.

3. The allergen reducing agent according to claim 1, characterized in that the imide compound comprises a polymer having repeating units including the structure shown in formula (1) or formula (2) above.

4. The allergen reducing agent according to claim 3, characterized in that the polymer has a repeating unit represented by formula (3) or formula (4). However, in formulas (3) and (4), n1 and n2 each represent the number of repeating units and are integers of 2 or more. In formulas (3) and (4), A 1 and A 2 These are alkylene groups. In formula (4), X is the countercation that forms the salt.

5. The allergen reducing agent according to claim 3, characterized in that the polymer has a structure represented by formula (3a) or formula (4a) for the repeating unit. However, in formulas (3a) and (4a), n1 and n2 represent the number of repeating units and are integers of 2 or more. In formula (4a), X is a countercation that forms a salt.

6. The allergen reducing agent according to claim 4, characterized in that the polymer further comprises repeating units including the structure shown in formula (5) or formula (6). However, in formula (5), m1 represents the number of repeating units and is an integer of 2 or more, and A 3 is an alkylene group. In formula (6), m² represents the number of repeating units and is an integer of 2 or more, A 4 Z is an alkylene group, and Z is the countercation that forms the salt. Multiple Z groups may be identical or different from each other.

7. The allergen reducing agent according to claim 4, characterized in that the polymer further comprises repeating units including the structure shown in formula (5a) or formula (6a). However, in formula (5a), m1 represents the number of repeating units and is an integer of 2 or more. In formula (6a), m2 represents the number of repeating units and is an integer of 2 or more. Z is a countercation that forms a salt. Multiple Zs may be the same or different from each other.

8. The allergen reducing agent according to claim 3, characterized in that the weight-average molecular weight of the polymer is 10,000 to 500,000.

9. The allergen reducing agent according to claim 3, characterized in that the polymer contains a crosslinked structure.

10. An allergen-reducing paint characterized by comprising a paint and an allergen-reducing agent according to claim 1 or claim 3 contained in the above paint.

Images